Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
José Manuel Pérez-García(MedSIR (Spain)), Géraldine Gebhart(Institut Jules Bordet), Manuel Ruíz Borrego(Hospital Universitario Virgen del Rocío), Agostina Stradella(Institut Català d'Oncologia), Begoña Bermejo(Hospital Clínico Universitario de Valencia), Peter Schmid(Barts Health NHS Trust), Frederik Marmé(University Hospital Heidelberg), Santiago Escrivá-de-Romaní(Vall d'Hebron Institute of Oncology), Lourdes Calvo(Complexo Hospitalario Universitario A Coruña), Nuria Ribelles(Hospital Clínico Universitario Virgen de la Victoria), Noelia Martínez-Jáñez(Hospital Universitario Ramón y Cajal), Cinta Albacar(Hospital Universitari Sant Joan de Reus), Aleix Prat(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Florence Dalenc(Institut Claudius Regaud), Khaldoun Kerrou(Assistance Publique – Hôpitaux de Paris), Marco Colleoni(Istituti di Ricovero e Cura a Carattere Scientifico), N. Afonso(Centro Hospitalar do Porto), Serena Di Cosimo(Medica (United States)), Miguel Sampayo-Cordero(MedSIR (Spain)), Andrea Malfettone(MedSIR (Spain)), Javier Cortés(MedSIR (Spain)), Antonio Llombart‐Cussac(MedSIR (Spain))
Cited by 157
Abstract
Related Papers
No related papers found
Powered by citation graph analysis